PD-159206
PD-159206 is an anti-HIV agent. PD-159206 inhibits early pre-integration steps of the HIV life cycle, and delays sequential progression of reverse transcription products. PD-159206 can be used for the research of HIV infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 171744-42-6
- Formule: C26H32N2O6S2
- Masse moléculaire:532.67
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
|
HIV-1 |
In Vitro
PD-159206 (5 days) inhibits replication of laboratory and clinical HIV-1 isolates, HIV-2, and SIV in H9, MT4, CEM, CEM-SS, PBMC, and macrophage cell systems[1].
PD-159206 (0.1-100 μM; 48 h) dose-dependently inhibits HIV-1 replication in HeLa-CD4-LTR-β-gal cells[1].
PD-159206 (20 μM; 48 h) inhibits early steps of the HIV-1 life cycle in HeLa-CD4-LTR-β-gal cells, with maximum effectiveness when added within the first 4 hours of infection and complete loss of activity by 6 hours post-infection[1].
PD-159206 (20 μM; 4-24 h) delays the progression of HIV-1 reverse transcription and prevents formation of 2LTR circles in H9 cells, indicating inhibition of pre-integration steps in the viral life cycle[1].
PD-159206 (0.1-100 μM; 48 h) shows no cytotoxicity up to 100 μM in HeLa Magi cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HeLa Magi cells
-
Concentration:0.1; 1; 3; 6; 12; 25; 50; 100 μM
-
Incubation Time:48 h
-
Result:Showed no cytotoxicity in HeLa Magi cells.
Remained cell viability above 80% at all tested concentration.
-
Cell Line:H9 cells infected with HIV-III B
-
Concentration:20 μM
-
Incubation Time:4; 12; 24 h
-
Result:Delayed the progression of HIV-1 reverse transcription and prevents formation of 2LTR circles in H9 cells.
Chemical Information
-
CAS No. 171744-42-6
-
Masse moléculaire 532.67
-
Formule C26H32N2O6S2
-
SMILES
O=C(C(C(CC)C)NC(C1=C(SSC2=C(C(NC(C(CC)C)C(O)=O)=O)C=CC=C2)C=CC=C1)=O)O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
[1]. Sharmeen L, et al. Inhibition of the early phase of HIV replication by an isothiazolone, PD 161374. Antiviral Res. 2001;49(2):101-114. [Content Brief]
[2]. Ye M, et al. Microdialysis sampling of the isothiazolone, PD-161374, and its thiol and disulfide metabolites. J Pharm Biomed Anal. 2000;24(2):273-280. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PD-159206 Related Classifications
HY-183663 Related Classifications
Powered by Bioz